Print
Email
Print Edition StoriesMonday, October 26, 2009
Thermo Fisher launches heart attack biomarker in Europe
By Mass High Tech staff
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: RI plans launch of cord blood center
Rodney Brown on NECN: Hacking into medical devices
Thermo Fisher Scientific Inc.’s acquisition last month of German firm BRAHMS AG is paying off quickly. The Waltham instrumentation firm’s Copeptin assay, developed by BRAHMS, has been launched in Europe as a biomarker for heart attack, the company announced, and is now commercially available throughout the continent.
The Copeptin assay is designed to diagnose acute myocardial infarction, known as a heart attack, within minutes of patients taking a blood test, alongside doctors’ use of a Troponin biomarker test.
The assay would replace the current role of an electrocardiogram, used with a Troponin test, which diagnoses a heart attack four hours after symptoms begin.
In the U.S., Thermo Fisher aims to provide data to the U.S. Food and Drug Administration by the end of 2010 to ready it for market.
Thermo Fisher announced its buyout of BRAHMS for $470 million in September. The German firm now operates as part of the Specialty Diagnostics unit of Thermo Fisher’s Analytical Technologies Segment.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
